Vassili Valayannopoulos

Vassili Valayannopoulos serves as the Executive Medical Director and Clinical Program Lead for Auditory Sciences and Rare Diseases at Regeneron, overseeing clinical activities for gene therapy programs related to congenital hearing loss since January 2024. Prior experience includes roles as Vice President and Head of Clinical Research and Development at Decibel Therapeutics, and Vice President Clinical Research at Ultragenyx Pharmaceutical Inc., where Vassili led an AAV-based gene therapy program. Additional positions at Sanofi Genzyme involved lifecycle management and development for the Rare Disease portfolio, alongside a distinguished scientific fellowship focusing on therapeutic strategies. Vassili's earlier experience includes managing a therapeutic unit for lysosomal disorders at Hôpital Necker-Enfants Malades. Vassili holds an MBA from MIT Sloan School of Management and a Ph.D. in Molecular Biology and Genetics from Université Paris Cité.